Korean J Pain.  2022 Jan;35(1):4-13. 10.3344/kjp.2022.35.1.4.

The evolving classifications and epidemiological challenges surrounding chronic migraine and medication overuse headache: a review

• Schembri E
• Barrow M
• McKenzie C
• Dawson A

• KMID: 2524640
• DOI: http://doi.org/10.3344/kjp.2022.35.1.4

Abstract

Changes in diagnostic criteria, for example, the various International Classification of Headache Disorders criteria, would lead to changes in the outcomes of epidemiological studies. International Classification of Headache Disorders-1 was based mainly on expert opinion, yet most of the diagnostic criteria were reliable and valid, but it did not include chronic migraine. In its second version, the classification introduced chronic migraine, but this diagnosis resembled more a high-frequency migraine rather than the actual migraine transformation process. It also introduced medication overuse headache, but it necessitated analgesic withdrawal and subsequent headache improvement to be diagnosed as such. Hence patients having medication overuse headache could only be diagnosed in retrospect, which was an awkward situation. Such restrictive criteria for chronic migraine and medication overuse headache omitted a high proportion of patients. International Classification of Headache Disorders-3 allows a diagnosis of medication overuse headache due to combination analgesics if taken for at least 10 days per month for more than three months. Hence the prevalence rate of medication overuse headache and chronic migraine can increase compared to the previous version of the headache classification. Different criteria have been used across studies to identify chronic migraine and medication overuse headache, and therefore the information acquired from previous studies using earlier criteria becomes uncertain. Hence much epidemiological research would need to be interpreted cautiously or repeated with the most updated criteria, since the subjects in studies that apply the latest criteria may be phenotypically different from those in older studies.

Keyword

Analgesics; Brain Diseases; Classification; Headache; Headache Disorders; Headache Disorders; Primary; Headache Disorders; Secondary; Migraine Disorders

Reference

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. 2018; Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 392:1789–858. DOI: 10.1016/S0140-6736(18)32279-7. PMID: 30496104. PMCID: PMC6227754.

2. GBD 2016 Headache Collaborators. 2018; Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 17:954–76. DOI: 10.1016/S1474-4422(18)30322-3. PMID: 30353868. PMCID: PMC6191530.

3. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. 2015; Headache disorders are third cause of disability worldwide. J Headache Pain. 16:58. DOI: 10.1186/s10194-015-0544-2. PMID: 26109437. PMCID: PMC4480232.

4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. 2017; Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 390:1211–59. DOI: 10.1016/S0140-6736(17)32154-2. PMID: 28919117. PMCID: PMC5605509.

5. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. 2017; Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 377:2113–22. DOI: 10.1056/NEJMoa1709038. PMID: 29171818.

6. Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P. 2016; Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 11:1045–57. DOI: 10.1007/s11739-016-1489-4. PMID: 27339365.

7. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al. 2012; The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 19:703–11. DOI: 10.1111/j.1468-1331.2011.03612.x. PMID: 22136117.

8. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, et al. 2014; The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 15:31. DOI: 10.1186/1129-2377-15-31. PMID: 24884549. PMCID: PMC4045992.

9. Steiner TJ, Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, et al. 2013; Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. J Headache Pain. 14:87. DOI: 10.1186/1129-2377-14-87. PMID: 24160915. PMCID: PMC4231353.

10. Headache Classification Subcommittee of the International Headache Society. 2004; The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 24 Suppl 1:9–160. DOI: 10.1111/j.1468-2982.2003.00824.x. PMID: 14979299.

11. Headache Classification Subcommittee of the International Headache Society. 2004; The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 24 Suppl 1:9–160. DOI: 10.1111/j.1468-2982.2003.00824.x. PMID: 14979299.

12. Headache Classification Committee of the International Headache Society (IHS). 2013; The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 33:629–808. DOI: 10.1177/0333102413485658. PMID: 23771276.

13. Headache Classification Committee of the International Headache Society (IHS). 2018; The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38:1–211. DOI: 10.1177/0333102417738202. PMID: 29368949.

14. Olesen J, Steiner TJ. 2004; The international classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry. 75:808–11. DOI: 10.1136/jnnp.2003.031286. PMID: 15145989. PMCID: PMC1739053.

15. Silberstein SD, Lipton RB, Solomon S, Mathew NT. 1994; Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache. 34:1–7. DOI: 10.1111/j.1526-4610.1994.hed3401001.x. PMID: 8132434.

16. Silberstein SD, Lipton RB, Sliwinski M. 1996; Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 47:871–5. DOI: 10.1212/WNL.47.4.871. PMID: 8857711.

17. Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. Headache Classification Committee. 2006; New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 26:742–6. DOI: 10.1111/j.1468-2982.2006.01172.x. PMID: 16686915.

18. Manzoni GC, Grisendi I, Torelli P. 2011; ICHD-3: what changes do we need regarding migraine? Curr Pain Headache Rep. 15:170–6. DOI: 10.1007/s11916-011-0188-0. PMID: 21365366.

19. Katsarava Z, Manack A, Yoon MS, Obermann M, Becker H, Dommes P, et al. 2011; Chronic migraine: classification and comparisons. Cephalalgia. 31:520–9. DOI: 10.1177/0333102410383590. PMID: 21220376.

20. Olesen J. 2006; International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. Cephalalgia. 26:1409–10. DOI: 10.1111/j.1468-2982.2006.01214.x. PMID: 17116090.

21. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. 2007; The International Classification of Headache Disorders revised criteria for chronic migraine-field testing in a headache specialty clinic. Cephalalgia. 27:230–4. DOI: 10.1111/j.1468-2982.2006.01274.x. PMID: 17263770.

22. Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. 2006; Field testing alternative criteria for chronic migraine. Cephalalgia. 26:477–82. DOI: 10.1111/j.1468-2982.2006.01128.x. PMID: 16556250.

23. Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, et al. 2010; Prevalence of chronic migraine and medication overuse headache in Germany--the German DMKG headache study. Cephalalgia. 30:207–13. DOI: 10.1111/j.1468-2982.2009.01906.x. PMID: 19489879.

24. Manzoni GC, Bonavita V, Bussone G, Cortelli P, Narbone MC, Cevoli S, et al. 2011; Chronic migraine classification: current knowledge and future perspectives. J Headache Pain. 12:585–92. DOI: 10.1007/s10194-011-0393-6. PMID: 22028184. PMCID: PMC3208036.

25. Jiang H, Deng Y, Zhang Y, Jin J, Kong X, Zhu Q, et al. 2016; Field testing of the ICHD-3β and expert opinion criteria for chronic migraine. J Headache Pain. 17:85. DOI: 10.1186/s10194-016-0678-x. PMID: 27644255. PMCID: PMC5028349.

26. May A, Schulte LH. 2016; Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 12:455–64. DOI: 10.1038/nrneurol.2016.93. PMID: 27389092.

27. Russell MB. 2019; Epidemiology and management of medication-overuse headache in the general population. Neurol Sci. 40(Suppl 1):23–6. DOI: 10.1007/s10072-019-03812-8. PMID: 30887240.

28. Goadsby PJ, Hargreaves R. 2008; Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache. 48:1399–405. DOI: 10.1111/j.1526-4610.2008.01274.x. PMID: 19006557.

29. Torres-Ferrús M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P. 2017; When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 37:104–13. DOI: 10.1177/0333102416636055. PMID: 26961321.

30. Manzoni GC, Torelli P. 2015; Chronic headaches: a clinician's experience of ICHD-3 beta. Neurol Sci. 36 Suppl 1:51–5. DOI: 10.1007/s10072-015-2142-0. PMID: 26017512.

31. Schwedt TJ, Chong CD. 2017; Medication overuse headache: pathophysiological insights from structural and functional brain MRI research. Headache. 57:1173–8. DOI: 10.1111/head.13037. PMID: 28160280.

32. Martelletti P. 2018; The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. J Headache Pain. 19:2. DOI: 10.1186/s10194-017-0830-2. PMID: 29322261. PMCID: PMC5762616.

33. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. 2015; Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388:1545–602. DOI: 10.1016/S0140-6736(16)31678-6. PMID: 27733282. PMCID: PMC5055577.

34. Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, et al. 2018; Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 19:50. DOI: 10.1186/s10194-018-0875-x. PMID: 30003412. PMCID: PMC6043466.

35. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. 2010; OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 30:793–803. DOI: 10.1177/0333102410364676. PMID: 20647170.

36. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. 2010; OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 30:804–14. DOI: 10.1177/0333102410364677. PMID: 20647171.

37. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. 2010; OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 50:921–36. DOI: 10.1111/j.1526-4610.2010.01678.x. PMID: 20487038.

38. National Institute for Health and Care Excellence (NICE). 2012. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine [Internet]. NICE;London: Available at: https://www.nice.org.uk/guidance/ta260/resources/botulinum-toxin-typea-for-the-prevention-of-headaches-in-adults-with-chronic-migraine-pdf-82600545273541.

39. Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. 2014; Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 34:409–25. DOI: 10.1177/0333102413512033. PMID: 24293089.

40. Stewart WF, Lipton RB, Celentano DD, Reed ML. 1992; Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 267:64–9. DOI: 10.1001/jama.1992.03480010072027. PMID: 1727198.

41. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. 2001; Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 41:646–57. DOI: 10.1046/j.1526-4610.2001.041007646.x. PMID: 11554952.

42. Winter AC, Berger K, Buring JE, Kurth T. 2012; Associations of socioeconomic status with migraine and non-migraine headache. Cephalalgia. 32:159–70. DOI: 10.1177/0333102411430854. PMID: 22174348. PMCID: PMC3266434.

43. Castillo J, Muñoz P, Guitera V, Pascual J. 1999; Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 39:190–6. DOI: 10.1046/j.1526-4610.1999.3903190.x. PMID: 15613213.

44. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. 2008; Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 48:1157–68. DOI: 10.1111/j.1526-4610.2008.01217.x. PMID: 18808500.

45. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. 2012; Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 52:1456–70. DOI: 10.1111/j.1526-4610.2012.02223.x. PMID: 22830411.

46. Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, et al. 2014; Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 15:3. DOI: 10.1186/1129-2377-15-3. PMID: 24400999. PMCID: PMC3906903.

47. Streel S, Donneau AF, Hoge A, Albert A, Schoenen J, Guillaume M. 2015; One-year prevalence of migraine using a validated extended French version of the ID Migraine™: a Belgian population-based study. Rev Neurol (Paris). 171:707–14. DOI: 10.1016/j.neurol.2015.04.009. PMID: 26239062.

48. Streel S, Donneau AF, Dardenne N, Hoge A, Bruyère O, Albert A, et al. 2015; Validation of an extended French version of ID Migraine™ as a migraine-screening tool. Cephalalgia. 35:437–42. DOI: 10.1177/0333102414544910. PMID: 25115843.

49. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, et al. 2003; A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology. 61:375–82. DOI: 10.1212/01.WNL.0000078940.53438.83. PMID: 12913201.

50. da Silva A Jr, Costa EC, Gomes JB, Leite FM, Gomez RS, Vasconcelos LP, et al. 2010; Chronic headache and comorbidities: a two-phase, population-based, cross-sectional study. Headache. 50:1306–12. DOI: 10.1111/j.1526-4610.2010.01620.x. PMID: 20163479.

51. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. 2012; Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain. 153:56–61. DOI: 10.1016/j.pain.2011.08.018. PMID: 22018971.

52. Global Burden of Disease Study 2013 Collaborators. 2015; Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 386:743–800. DOI: 10.1016/S0140-6736(15)60692-4. PMID: 26063472. PMCID: PMC4561509.

53. Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, et al. 2017; Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 18:101. DOI: 10.1186/s10194-017-0787-1. PMID: 28980171. PMCID: PMC5628086.

54. Steiner TJ, Stovner LJ. 2019. Societal impact of headache: burden, costs and response. Springer;Cham: p. 83–104. https://www.worldcat.org/title/societal-impact-of-headache-burden-costs-and-response/oclc/1104058606?referer=br&ht=edition. DOI: 10.1007/978-3-030-24728-7_8.